Greer has finished enrolling patients for its Phase III clinical trial studying sublingual-oral immunotherapy as a treatment for adults with allergic rhinoconjunctivitis caused by short ragweed pollen.  Read More

Using Merck’s investigational drug telcagepant, a Phase III trial showed improvement in patients’ pain and symptom relief from migraines.  Read More

After disappointing Phase III trial results, Myriad is discontinuing its development of Flurizan for Alzheimer’s disease.  Read More

DOR BioPharma is collaborating with Numoda, a clinical trials information services company, in its upcoming confirmatory Phase III clinical trial of orBec in the treatment of gastrointestinal graft-versus-host disease (GI GVHD).  Read More

Vivus’ Phase II study for Qnexa, used for treating cardiovascular complications that arise from Type 2 diabetes, produced positive results.  Read More

Mpex Pharmaceuticals has begun a Phase II clinical study with MP-376 for the treatment of pulmonary infections in patients with cystic fibrosis (CF).  Read More

MethylGene has initiated a Phase II clinical trial evaluating MGCD0103 in combination with injections of Vidaza for patients with high-risk myelodysplastic syndromes or acute myeloid leukemia.  Read More

GPC Biotech is beginning a clinical trial testing satraplatin combined with the steroid prednisone in patients with metastatic hormone-refractory prostate cancer who have been treated with docetaxel, a chemotherapy drug.  Read More

Patients who are addicted to methamphetamine are enrolling in Catalyst Pharmaceuticals’ Phase II clinical trial using CPP-109.  Read More

A Phase II clinical trial is under way for BioMarck Pharmaceuticals’ study of BIO-11006 inhalation solution for chronic obstructive pulmonary disease (COPD).  Read More